32
Malignancy
- July Update
•36 malignancies in 31 subjects
30 malignancies
in 26 subjects
2 placebo
switched→open-label raltegravir
*Double Blind: 22 in 19
subjects
6 malignancies in 5 subjects
2 in 1 EFV-treated subject
4 in placebo-treated subjects
Raltegravir
Control
1
200
mg raltegravir
005
1
400
mg raltegravir
4
Placebo
018/019
21
400
mg raltegravir
2
400
mg raltegravir
1
200
mg raltegravir
1
EFV
004
N
subjects with Malignancy
Treatment
Arm
Protocol